Targeting the stromal-immune barrier: A novel strategy to overcome resistance to CLDN18.2/CD3 bispecific T-cell engager therapy in pancreatic cancer

Cancer Letters 2026

View at publisher

Authors: S.-Y. Liu, S.-Y. Liu, Matthäus Felsenstein, Shaokun Liu, Shaokun Liu, Igor Maximilian Sauer, Muhammad Ashraf

DOI: 10.1016/j.canlet.2026.218248

Cited by: 0

References: 10

Fields of Study & Subjects

CAR-T cell therapy research Monoclonal and Polyclonal Antibodies Research Cancer Immunotherapy and Biomarkers

References 10